<DOC>
	<DOC>NCT01518387</DOC>
	<brief_summary>The purpose of this study is to assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (lanthanum carbonate) in patients with hyperphosphatemia undergoing continuous ambulatory peritoneal dialysis.</brief_summary>
	<brief_title>Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Serum phosphate levels: &gt;5.0 mg/dL and &lt;11.0 mg/dL 2 weeks after the initiation of the washout period Outpatient Undergoing CAPD for at least previous 3 consecutive months Who may not enable to continue CAPD Serum phosphate levels of &gt;=10.0 mg/dL at the start of the washout period or &gt;=11.0 mg/dL 2 week after Corrected serum calcium level of &lt;7.0 mg/dL at the start of the washout period or &gt;=11.0 mg/dL 2 week after Serum intact PTH (Parathyroid) of &gt;=1000 pg/mL at the start of the washout period Pregnant woman, or lactating mother Significant gastrointestinal disorders including known acute peptic ulcer Liver dysfunction History of cardiovascular or cerebrovascular diseases</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hyperphosphatemia in ESRD (End Stage Renal Disease) patients on dialysis</keyword>
</DOC>